Myriad Genetics, Inc. (MYGN)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 49/100 (MEDIUM), 16.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 9.94% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
- What Myriad Genetics Doubters Saw Before The Drop
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
- Myriad Genetics (MYGN) Stock Sees Fair Value Lift As Analysts Weigh Split Targets
- 3 Reasons MYGN is Risky and 1 Stock to Buy Instead
- Myriad Genetics (MYGN) Stock Fair Value Moves Lower After Analyst Cuts And Guidance Reset
- 1 Unpopular Stock That Deserves Some Love and 2 We Turn Down
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Myriad Genetics, Inc..
Full MYGN Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.